Inventiva S.A.
IVA•NASDAQ•Healthcare•Biotechnology

About Inventiva

Inventiva S.A., a clinical-stage biopharmaceutical company, focuses on the development of oral small molecule therapies for the treatment of metabolic dysfunction-associated steatohepatitis (MASH) and other diseases in France and internationally. The company develops Lanifibranor, a novel pan-peroxisome proliferator-activated receptor agonist that is in the NATiV3 Phase 3 clinical trial to treat adult patients with MASH; and Odiparcil for the treatment of patients with mucopolysaccharidoses. It also develops TGF-β, a pre-clinical program for the treatment of idiopathic pulmonary fibrosis. The company was incorporated in 2011 and is headquartered in Daix, France.

Company Information

SectorHealthcare
IndustryBiotechnology
CEOAndrew Obenshain
Founded2011
IPO DateJuly 10, 2020
Employees118
CountryFrance
Fiscal YearJanuary - December

Stock Details

ExchangeNASDAQ (NASDAQ)
CurrencyEUR - EUR
TypeStock

Contact Information

Websiteinventivapharma.com
Phone33 3 80 44 75 00
Address
50 rue de Dijon Daix, 21121 France

Corporate Identifiers

CIK0001756594
CUSIP46124U107
ISINUS46124U1079
SIC2834

Leadership Team & Key Executives

Andrew Obenshain
Chief Executive Officer and Director
Dr. Pierre Broqua Ph.D.
Co-Founder
Dr. Martine Zimmermann Pharm.D.
Executive Vice President of Regulatory Affairs and Quality Assurance
Jean Volatier
Deputy GM and Chief Financial Officer
Alice Roudot-Ketelers Pharm.D.
Chief Operating Officer
Eric Duranson L.L.M.
General Counsel
Nathalie Harroy
Head of Human Resources
Pascaline Clerc Ph.D.
Executive Vice President of Strategy and Corporate Affairs
Jason A. Campagna M.D., Ph.D.
President of Research and Development and Chief Medical Officer